{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T09:40:17Z","timestamp":1720518017761},"reference-count":30,"publisher":"Spandidos Publications","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2018.9321","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T07:26:20Z","timestamp":1534490780000},"source":"Crossref","is-referenced-by-count":0,"title":["PSA response following the \u2018steroid switch\u2019 in patients with castration\u2011resistant prostate cancer treated with abiraterone: A case report"],"prefix":"10.3892","author":[{"given":"Tomonori","family":"Kato","sequence":"first","affiliation":[{"name":"Department of Urology, Teikyo University Chiba Medical Center, Ichihara, Chiba 299\u20110111, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Kojima","sequence":"additional","affiliation":[{"name":"Department of Urology, Teikyo University Chiba Medical Center, Ichihara, Chiba 299\u20110111, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumi","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Urology, Teikyo University Chiba Medical Center, Ichihara, Chiba 299\u20110111, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotaro","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Urology, Teikyo University Chiba Medical Center, Ichihara, Chiba 299\u20110111, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahito","family":"Suyama","sequence":"additional","affiliation":[{"name":"Department of Urology, Teikyo University Chiba Medical Center, Ichihara, Chiba 299\u20110111, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyokushin","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Urology, Teikyo University Chiba Medical Center, Ichihara, Chiba 299\u20110111, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Araki","sequence":"additional","affiliation":[{"name":"Department of Urology, Teikyo University Chiba Medical Center, Ichihara, Chiba 299\u20110111, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Urology, Teikyo University Chiba Medical Center, Ichihara, Chiba 299\u20110111, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuto","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"Department of Pathology, Teikyo University Chiba Medical Center, Ichihara, Chiba 299\u20110111, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Komiya","sequence":"additional","affiliation":[{"name":"Department of Urology, Chiba University Graduate School of Medicine, Chiba, Chiba 260\u20118677, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Naya","sequence":"additional","affiliation":[{"name":"Department of Urology, Teikyo University Chiba Medical Center, Ichihara, Chiba 299\u20110111, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2018,8,17]]},"reference":[{"key":"key20200714084137_b1-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"key20200714084137_b2-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"key20200714084137_b3-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomized controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"key20200714084137_b4-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"key20200714084137_b5-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11916-012-0273-z","article-title":"The role of corticosteroids in the treatment of pain in cancer patients","volume":"16","author":"Leppert","year":"2012","journal-title":"Curr Pain Headache Rep"},{"key":"key20200714084137_b6-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4158\/EP.7.1.11","article-title":"Corticosteroid-induced inhibition of adrenal androgen production in selected patients with prostate cancer","volume":"7","author":"Khandwala","year":"2001","journal-title":"Endocr Pract"},{"key":"key20200714084137_b7-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.mce.2011.09.038","article-title":"Putting the brakes on continued androgen receptor signaling in castration resistant prostate cancer","volume":"360","author":"Eichholz","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"key20200714084137_b8-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3892\/ol_00000013","article-title":"Oral low-dose dexamethasone for androgen-independent prostate cancer patients","volume":"1","author":"Komiya","year":"2010","journal-title":"Oncol Lett"},{"key":"key20200714084137_b9-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.eururo.2014.10.004","article-title":"A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer","volume":"67","author":"Venkitaraman","year":"2015","journal-title":"Eur Urol"},{"key":"key20200714084137_b10-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1038\/bjc.2014.531","article-title":"Tumour responses following a steroid switch from prednisone to dexamethasone in castration resistant prostate cancer patients progressing on abiraterone","volume":"111","author":"Lorente","year":"2014","journal-title":"Br J Cancer"},{"key":"key20200714084137_b11-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"e133","DOI":"10.1016\/j.clgc.2014.01.008","article-title":"Abiraterone-what is wrong with the adrenal glands?","volume":"12","author":"Schmid","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"key20200714084137_b12-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1200\/JCO.1989.7.5.590","article-title":"Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response","volume":"7","author":"Tannock","year":"1989","journal-title":"J Clin Oncol"},{"key":"key20200714084137_b13-ol-0-0-9321","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1464-410X.2007.07261.x","article-title":"Efficacy of low-dose dexamethasone in castration-refractory prostate cancer","volume":"101","author":"Venkitaraman","year":"2008","journal-title":"BJU Int"},{"key":"key20200714084137_b14-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.urology.2016.02.010","article-title":"Practical guidance on the role of corticosteroids in the treatment of metastatic castration resistant prostate cancer","volume":"96","author":"De Santis","year":"2016","journal-title":"Urology"},{"key":"key20200714084137_b15-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S0022-5347(05)67815-9","article-title":"Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer","volume":"163","author":"Weitzman","year":"2000","journal-title":"J Urol"},{"key":"key20200714084137_b16-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1055\/s-2004-814578","article-title":"Pharmacodynamics and pharmacokinetics of synthetic mineralocorticoids and glucocorticoids: Receptor transactivation and prereceptor metabolism by 11beta-hydroxysteroid-dehydrogenases","volume":"36","author":"Diederich","year":"2004","journal-title":"Horm Metab Res"},{"key":"key20200714084137_b17-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/1097-0142(20001215)89:12<2570::AID-CNCR9>3.0.CO;2-H","article-title":"Low doses of oral dexamethasone for hormone-refractory prostate carcinoma","volume":"89","author":"Nishimura","year":"2000","journal-title":"Cancer"},{"issue":"pii","key":"key20200714084137_b18-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"E67","DOI":"10.3390\/cancers9060067","article-title":"Androgen receptor-dependent and -independent mechanisms involved in prostate cancer therapy resistance","volume":"9","author":"Crona","year":"2017","journal-title":"Cancers (Basel)"},{"key":"key20200714084137_b19-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Arora","year":"2013","journal-title":"Cell"},{"key":"key20200714084137_b20-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1210\/jcem-54-2-332","article-title":"Binding of steroids to mineralocorticoid receptors: Implications for in vivo occupancy by glucocorticoids","volume":"54","author":"Lan","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"key":"key20200714084137_b21-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jsbmb.2009.04.007","article-title":"Differential expression of determinants of glucocorticoid sensitivity in androgen-dependent and androgen-independent human prostate cancer cell lines","volume":"116","author":"Dovio","year":"2009","journal-title":"J Steroid Biochem Mol Biol"},{"key":"key20200714084137_b22-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"T85","DOI":"10.1530\/ERC-16-0319","article-title":"Women in Cancer Thematic Review: New roles for nuclear receptors in prostate cancer","volume":"23","author":"Leach","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"key20200714084137_b23-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJM199505253322101","article-title":"Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer","volume":"332","author":"Taplin","year":"1995","journal-title":"N Engl J Med"},{"key":"key20200714084137_b24-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/76287","article-title":"Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor","volume":"6","author":"Zhao","year":"2000","journal-title":"Nat Med"},{"key":"key20200714084137_b25-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1158\/0008-5472.CAN-11-3980","article-title":"Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: A rationale for increasing abiraterone exposure or combining with MDV3100","volume":"72","author":"Richards","year":"2012","journal-title":"Cancer Res"},{"key":"key20200714084137_b26-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1093\/jnci\/93.22.1739","article-title":"Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer","volume":"93","author":"Nishimura","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"key20200714084137_b27-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0022-5347(05)00034-0","article-title":"Secondary hormonal therapy for advanced prostate cancer","volume":"175","author":"Lam","year":"2006","journal-title":"J Urol"},{"key":"key20200714084137_b28-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"3003","DOI":"10.1158\/1078-0432.CCR-06-0749","article-title":"Glucocorticoids suppress tumor angiogenesis and in vivo growth of prostate cancer cells","volume":"12","author":"Yano","year":"2006","journal-title":"Clin Cancer Res"},{"key":"key20200714084137_b29-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/pros.10231","article-title":"Possible mechanism of dexamethasone therapy for prostate cancer: Suppression of circulating level of interleukin-6","volume":"56","author":"Akakura","year":"2003","journal-title":"Prostate"},{"key":"key20200714084137_b30-ol-0-0-9321","doi-asserted-by":"publisher","first-page":"7076","DOI":"10.1074\/jbc.M108255200","article-title":"Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways","volume":"277","author":"Ueda","year":"2002","journal-title":"J Biol Chem"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T09:09:39Z","timestamp":1720516179000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2018.9321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,17]]},"references-count":30,"URL":"https:\/\/doi.org\/10.3892\/ol.2018.9321","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,17]]}}}